Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Organ-specific metastatic landscape dissects PD-(L)1 blockade efficacy in advanced non-small cell lung cancer: applicability from clinical trials to real-world practice

Fig. 3

Predictive significance of metastatic-organ landscape for efficacy with immunotherapy versus chemotherapy in a PD-L1-dependent fashion. Forest plots showing overall survival (OS) benefits of atezolizumab versus docetaxel per organ metastatic category in A the total, B PD-L1-positive (TC/IC ≥ 1%), and C PD-L1-negative (TC/IC < 1%) populations from OAK trial. Two categories of metastatic organs were identified based on OS benefits of atezolizumab versus docetaxel in the PD-L1-positive population, and metastases to category I organ (adrenal glands, brain, and liver) presented significantly better OS results in atezolizumab arm versus docetaxel arm, while metastases to category II organ (bone, pleura, pleural effusion, and mediastinum) derived no benefit from atezolizumab over docetaxel. Abbreviations: Atezo, atezolizumab; Doce, docetaxel; CI, confidence interval; PD-L1, programmed death-ligand 1; TC, tumor cell; IC, immune cell

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us